AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020
Shots:
- The P-lll DAPA-CKD study involves the assessing of Farxiga (qd- 10 mg) + SOC vs PBO in 4304 patients with CKD stages 2-4 and elevated urinary albumin excretion- with/ out T2D
- Results of subgroup analysis : RRR & ARR (5.8% & 37%) for patients whose CKD was primarily driven by diabetic kidney disease; (25% & 2.2%) for high B.P.; (57% & 7.5%) for glomerulonephritis; (42% & 5.0%) for CKD of other or unknown causes (ARR = 5.0%) respectively. Also showed reduction in in all-cause mortality as secondary outcome
- Farxiga (PO- qd) is a first-in-class SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monotherapy & combination regimen as an adjunct to diet and exercise to improve glycemic control and has received FDA’s BTD & CHMP’s recommendation in Oct’2020
Ref: AstraZeneca | Image: NPR
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com